Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Last updated: May 15, 2025
Sponsor: Intellia Therapeutics
Overall Status: Active - Recruiting

Phase

N/A

Condition

Amyloidosis

Circulation Disorders

Treatment

N/A

Clinical Study ID

NCT05697861
ITL-2001-CL-999
2022-003405-30
  • Ages > 18
  • All Genders

Study Summary

This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. A subject has completed or discontinued from an Intellia-sponsored clinical study inwhich a complete or partial dose of NTLA-2001 was received.

  2. A subject has provided informed consent for the LTFU study.

Exclusion

Exclusion Criteria:

None

Study Design

Total Participants: 72
Study Start date:
July 10, 2023
Estimated Completion Date:
March 31, 2038

Connect with a study center

  • Clinical Trial Site

    Paris,
    France

    Active - Recruiting

  • Clinical Trial Site

    Auckland,
    New Zealand

    Active - Recruiting

  • Clinical Trial Site

    Umea,
    Sweden

    Active - Recruiting

  • Clinical Trial Site

    London,
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.